INSPIRE Turkey :A Research Study Looking at the Clinical Parameters Associated With Use and Discontinuation of Saxenda® in Local Clinical Practice in Turkey by Analysing Past Patient Medical Records

Inclusion Criteria: * Patients who have signed consent before any study-related activities (study-related activities are any procedure related to recording of data according to the protocol). * Patients who have polyclinic visits between 01 June 2022 and 31 October 2022 and who have received initial prescription of Saxenda® for weight management at least 52 weeks prior to study enrolment. * Patients who have maintained treatment with Saxenda® for at least 16 weeks, without treatment break, following the initial prescription. * Patients who have 12-month follow-up data, even if discontinued Saxenda ® treatment. * Patients who have body weight measurement at baseline and at least 1 more body weight measurement following the Saxenda® prescription * Age greater than or equal 18 years at the time of signing informed consent Exclusion criteria: * Mental incapacity, unwillingness or language barriers precluding adequate understanding or cooperation * Patient charts lacking any follow-up information for at least 16 weeks. * Patients who have been treated with anti-obesity medication for last 12 weeks prior to initiation of Saxenda® treatment. * Patients who receive GLP-1 receptor agonist for treatment of Type 2 diabetes. * Patients who have undergone bariatric surgery or use of minimal-invasive weight loss devices (i.e. intragastric balloons, lap bands) within 1 year before starting Saxenda® treatment.